NCT04203511 INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) Status WITHDRAWN Phase PHASE3
NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Status COMPLETED Phase PHASE2/PHASE3
NCT03920839 INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Status WITHDRAWN Phase PHASE1
NCT03910530 A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT03679767 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Status COMPLETED Phase PHASE2
NCT03599713 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) Status COMPLETED Phase PHASE2
NCT03597295 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) Status COMPLETED Phase PHASE2
NCT03589651 INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT03532295 Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Status COMPLETED Phase PHASE2
NCT03059823 A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02475213 Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer Status COMPLETED Phase PHASE1
NCT02393248 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Status TERMINATED Phase PHASE1/PHASE2